TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis
Brief Summary: The purpose of the study was to evaluate the effects of integrated treatment for patients with a first episode of psychotic illness. We conducted a randomised clinical trial in Copenhagen Hospital Corporation and Psychiatric Hospital Aarhus, Denmark. We included 547 patients with first episode of schizophrenia spectrum disorder, who has not received antipsychotic medication for more than 12 weeks.

Patients were randomised to integrated treatment or standard treatment. The integrated treatment lasted for two years and consisted of assertive community treatment with programmes for family involvement and social skills training. Standard treatment offered contact with a community mental health centre.

We wanted to study the effect on psychotic (hallucinations and delusions)and negative (lack of initiative, apati, blunted affect) symptoms (each scored from 0 to a maximum of 5) at one and two years' follow-up.

We found that integrated treatment improved clinical outcome and adherence to treatment. The improvement in clinical outcome was consistent at one year and two year follow-ups. We will study further outcome measures such as social network, quality of life, depression and suicidal behaviour.


Options:
A: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care
B: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
C: Arm Label: Case Management (1 year); Type: EXPERIMENTAL; Interventions: Behavioral: Community Case Management | Arm Label: Standard Care (1 year); Type: NO_INTERVENTION; Interventions: Behavioral: Community Case Management | Intervention Type: BEHAVIORAL; Name: Community Case Management; Assigned to Arm(s): Case Management (1 year), Standard Care (1 year)
D: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis
Brief Summary: The purpose of the study was to evaluate the effects of integrated treatment for patients with a first episode of psychotic illness. We conducted a randomised clinical trial in Copenhagen Hospital Corporation and Psychiatric Hospital Aarhus, Denmark. We included 547 patients with first episode of schizophrenia spectrum disorder, who has not received antipsychotic medication for more than 12 weeks.

Patients were randomised to integrated treatment or standard treatment. The integrated treatment lasted for two years and consisted of assertive community treatment with programmes for family involvement and social skills training. Standard treatment offered contact with a community mental health centre.

We wanted to study the effect on psychotic (hallucinations and delusions)and negative (lack of initiative, apati, blunted affect) symptoms (each scored from 0 to a maximum of 5) at one and two years' follow-up.

We found that integrated treatment improved clinical outcome and adherence to treatment. The improvement in clinical outcome was consistent at one year and two year follow-ups. We will study further outcome measures such as social network, quality of life, depression and suicidal behaviour.


Options:
A: Arm Label: 5 year; Type: EXPERIMENTAL; Interventions: Behavioral: OPUS 5 years | Arm Label: 2 years of OPUS treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 years OPUS treatment | Intervention Type: BEHAVIORAL; Name: 2 years OPUS treatment; Assigned to Arm(s): 2 years of OPUS treatment | Intervention Type: BEHAVIORAL; Name: OPUS 5 years; Assigned to Arm(s): 5 year
B: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A
C: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive training | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis
Brief Summary: The purpose of the study was to evaluate the effects of integrated treatment for patients with a first episode of psychotic illness. We conducted a randomised clinical trial in Copenhagen Hospital Corporation and Psychiatric Hospital Aarhus, Denmark. We included 547 patients with first episode of schizophrenia spectrum disorder, who has not received antipsychotic medication for more than 12 weeks.

Patients were randomised to integrated treatment or standard treatment. The integrated treatment lasted for two years and consisted of assertive community treatment with programmes for family involvement and social skills training. Standard treatment offered contact with a community mental health centre.

We wanted to study the effect on psychotic (hallucinations and delusions)and negative (lack of initiative, apati, blunted affect) symptoms (each scored from 0 to a maximum of 5) at one and two years' follow-up.

We found that integrated treatment improved clinical outcome and adherence to treatment. The improvement in clinical outcome was consistent at one year and two year follow-ups. We will study further outcome measures such as social network, quality of life, depression and suicidal behaviour.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 fatty acids | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Omega 3 fatty acids | Intervention Type: DRUG; Name: Omega 3 fatty acids; Assigned to Arm(s): A, B
B: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A
C: Arm Label: Glycine; Type: EXPERIMENTAL; Interventions: Drug: Glycine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycine; Assigned to Arm(s): Glycine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: BI 409306; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 409306; Assigned to Arm(s): BI 409306 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis
Brief Summary: The purpose of the study was to evaluate the effects of integrated treatment for patients with a first episode of psychotic illness. We conducted a randomised clinical trial in Copenhagen Hospital Corporation and Psychiatric Hospital Aarhus, Denmark. We included 547 patients with first episode of schizophrenia spectrum disorder, who has not received antipsychotic medication for more than 12 weeks.

Patients were randomised to integrated treatment or standard treatment. The integrated treatment lasted for two years and consisted of assertive community treatment with programmes for family involvement and social skills training. Standard treatment offered contact with a community mental health centre.

We wanted to study the effect on psychotic (hallucinations and delusions)and negative (lack of initiative, apati, blunted affect) symptoms (each scored from 0 to a maximum of 5) at one and two years' follow-up.

We found that integrated treatment improved clinical outcome and adherence to treatment. The improvement in clinical outcome was consistent at one year and two year follow-ups. We will study further outcome measures such as social network, quality of life, depression and suicidal behaviour.


Options:
A: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care
B: Arm Label: 5 year; Type: EXPERIMENTAL; Interventions: Behavioral: OPUS 5 years | Arm Label: 2 years of OPUS treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 years OPUS treatment | Intervention Type: BEHAVIORAL; Name: 2 years OPUS treatment; Assigned to Arm(s): 2 years of OPUS treatment | Intervention Type: BEHAVIORAL; Name: OPUS 5 years; Assigned to Arm(s): 5 year
C: Arm Label: Individual psychoeducation; Type: EXPERIMENTAL; Interventions: Other: Individual psychoeducation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Individual psychoeducation; Assigned to Arm(s): Individual psychoeducation
D: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis
Brief Summary: The purpose of the study was to evaluate the effects of integrated treatment for patients with a first episode of psychotic illness. We conducted a randomised clinical trial in Copenhagen Hospital Corporation and Psychiatric Hospital Aarhus, Denmark. We included 547 patients with first episode of schizophrenia spectrum disorder, who has not received antipsychotic medication for more than 12 weeks.

Patients were randomised to integrated treatment or standard treatment. The integrated treatment lasted for two years and consisted of assertive community treatment with programmes for family involvement and social skills training. Standard treatment offered contact with a community mental health centre.

We wanted to study the effect on psychotic (hallucinations and delusions)and negative (lack of initiative, apati, blunted affect) symptoms (each scored from 0 to a maximum of 5) at one and two years' follow-up.

We found that integrated treatment improved clinical outcome and adherence to treatment. The improvement in clinical outcome was consistent at one year and two year follow-ups. We will study further outcome measures such as social network, quality of life, depression and suicidal behaviour.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Computer-Based Cognitive Enhancement Training Program, Behavioral: Work Therapy Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Work Therapy Program | Intervention Type: BEHAVIORAL; Name: Computer-Based Cognitive Enhancement Training Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Work Therapy Program; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A
C: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care
D: Arm Label: Individual Placement and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support | Arm Label: Ordinary employment schemes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary employment schemes | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support; Assigned to Arm(s): Individual Placement and Support | Intervention Type: BEHAVIORAL; Name: Ordinary employment schemes; Assigned to Arm(s): Ordinary employment schemes

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes
Brief Summary: Diabetes mellitus is one of the most common diseases globally, and is considered epidemic in many developed and newly industrialized nations. Diabetes mellitus represents the single largest cause of end-stage renal disease in the U.S. and Europe. At the same time, the primary cause of early death in diabetic patients are cardiovascular complications. Experimental and clinical studies found that angiotensin converting enzyme inhibitors (ACEi) and calcium channel blockers (CCBs) have a specific renoprotective effect and that this effect can be magnified when the two drugs are used in combination. To formally test this hypothesis we designed the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) study, a prospective, randomized, double blind trial aimed to compare the effect of 3 years treatment with the ACEi Delapril (30 mg/day), alone or combined to the CCB Manidipine (10 mg/day), versus conventional (non ACEi, non CCB) therapy on the rate of renal function loss and on the incidence of major cardiovascular events in 342 normo- and micro-albuminuric hypertensive type 2 diabetic patients.


Options:
A: Arm Label: Arm 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Behavioral intervention with Home BP Telemonitoring | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Medication Management with Home BP Telemonitoring | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Combined intervention with Home BP Telemonitoring | Intervention Type: BEHAVIORAL; Name: Nurse Behavioral intervention with Home BP Telemonitoring; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Nurse Medication Management with Home BP Telemonitoring; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: Nurse Combined intervention with Home BP Telemonitoring; Assigned to Arm(s): Arm 4
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: optimised treatment | Intervention Type: PROCEDURE; Name: optimised treatment; Assigned to Arm(s): Intervention
C: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes
Brief Summary: Diabetes mellitus is one of the most common diseases globally, and is considered epidemic in many developed and newly industrialized nations. Diabetes mellitus represents the single largest cause of end-stage renal disease in the U.S. and Europe. At the same time, the primary cause of early death in diabetic patients are cardiovascular complications. Experimental and clinical studies found that angiotensin converting enzyme inhibitors (ACEi) and calcium channel blockers (CCBs) have a specific renoprotective effect and that this effect can be magnified when the two drugs are used in combination. To formally test this hypothesis we designed the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) study, a prospective, randomized, double blind trial aimed to compare the effect of 3 years treatment with the ACEi Delapril (30 mg/day), alone or combined to the CCB Manidipine (10 mg/day), versus conventional (non ACEi, non CCB) therapy on the rate of renal function loss and on the incidence of major cardiovascular events in 342 normo- and micro-albuminuric hypertensive type 2 diabetic patients.


Options:
A: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
C: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes
Brief Summary: Diabetes mellitus is one of the most common diseases globally, and is considered epidemic in many developed and newly industrialized nations. Diabetes mellitus represents the single largest cause of end-stage renal disease in the U.S. and Europe. At the same time, the primary cause of early death in diabetic patients are cardiovascular complications. Experimental and clinical studies found that angiotensin converting enzyme inhibitors (ACEi) and calcium channel blockers (CCBs) have a specific renoprotective effect and that this effect can be magnified when the two drugs are used in combination. To formally test this hypothesis we designed the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) study, a prospective, randomized, double blind trial aimed to compare the effect of 3 years treatment with the ACEi Delapril (30 mg/day), alone or combined to the CCB Manidipine (10 mg/day), versus conventional (non ACEi, non CCB) therapy on the rate of renal function loss and on the incidence of major cardiovascular events in 342 normo- and micro-albuminuric hypertensive type 2 diabetic patients.


Options:
A: Intervention Type: DRUG; Name: Valsartan + amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Valsartan + HCTZ; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amlodipine + HCTZ; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Valsartan + amlodipine + HCTZ; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium channel blockers (amlodipine, azelnidipine) | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Calcium channel blockers (amlodipine, azelnidipine); Assigned to Arm(s): 2
D: Arm Label: Valsartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valsartan | Arm Label: Amlodipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): Valsartan | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Control Trial of a Clinical Pathway for Nursing Home Pneumonia.
Brief Summary: Nursing home residents are frequently transferred to hospital for management of pneumonia. This often leads to hospital related complications and is a burden on the acute care health system. The purpose of this study is to assess whether managing residents with pneumonia and lower respiratory tract infection on site in the nursing home can reduce hospital admissions and can reduce complications and improve quality of life for residents. We have randomized residents with nursing home acquired pneumonia to on-site management, using a clinical pathway, versus usual care.


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Procedure: a clinical pathway nursing home acquired pneumonia | Arm Label: Comparator; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: a clinical pathway nursing home acquired pneumonia; Assigned to Arm(s): Intervention
B: Arm Label: Immediate INTERACT implementation; Type: EXPERIMENTAL; Interventions: Other: INTERACT Quality improvement program | Arm Label: Delayed intervention with reporting; Type: ACTIVE_COMPARATOR; Interventions: Other: Quarterly surveys/data reporting | Arm Label: Delayed intervention not reporting; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: INTERACT Quality improvement program; Assigned to Arm(s): Immediate INTERACT implementation | Intervention Type: OTHER; Name: Quarterly surveys/data reporting; Assigned to Arm(s): Delayed intervention with reporting
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: ACP+ programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACP+ programme; Assigned to Arm(s): Intervention group
D: Arm Label: Self management; Type: EXPERIMENTAL; Interventions: Behavioral: Self management program | Intervention Type: BEHAVIORAL; Name: Self management program; Assigned to Arm(s): Self management | Intervention Type: BEHAVIORAL; Name: self management program; Assigned to Arm(s): Self management

Answer: A